Eric O. Freed

Dr. Eric O. Freed

National Cancer Institute, Frederick, Maryland, USA
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2015 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
Eric O. FreedEric O. Freed
Eric O. Freed

20 November 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Akira OnoAkira Ono
Akira Ono
Eric O. FreedEric O. Freed
Eric O. Freed
HIV-1 particle production occurs in a series of steps promoted by the viral Gag protein. Although it is well established that assembly and release take place at the plasma membrane, the nature of membrane assembly sites remains poorly understood. We show here that Gag specifically associates with cholesterol-enriched microdomains (“rafts”) at the plasma membrane. Kinetic studies demonstrate that raft association follows membrane binding, and the analysis of Gag mutants reveals that, whereas the N terminus of Gag mediates raft binding, this association is greatly enhanced by Gag–Gag interaction domains. We observe that depletion of cellular cholesterol markedly and specifically reduces HIV-1 particle production. Furthermore, treatment of virus-producing cells or virus particles with raft-disrupting agents significantly impairs virus infectivity. These results identify the association of Gag with plasma membrane rafts as an important step in HIV-1 replication. These findings may lead to novel strategies for suppressing HIV-1 replication in vivo .

1 November 1998 in Virology
Verified
Journal Article
Closed access
Eric O. FreedEric O. Freed
Eric O. Freed

12 October 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Akira OnoAkira Ono
Akira Ono
SASherimay D. Ablan
Sherimay D. Ablan
SLStephen J. Lockett
Stephen J. Lockett
KNKunio Nagashima
Kunio Nagashima
Eric O. FreedEric O. Freed
Eric O. Freed
A critical early event in the HIV type 1 (HIV-1) particle assembly pathway is the targeting of the Gag protein to the site of virus assembly. In many cell types, assembly takes place predominantly at the plasma membrane. Cellular factors that regulate Gag targeting remain undefined. The phosphoinositide phosphatidylinositol (4,5) bisphosphate [PI(4,5)P 2 ] controls the plasma membrane localization of a number of cellular proteins. To explore the possibility that this lipid may be involved in Gag targeting and virus particle production, we overexpressed phosphoinositide 5-phosphatase IV, an enzyme that depletes cellular PI(4,5)P 2 , or overexpressed a constitutively active form of Arf6 (Arf6/Q67L), which induces the formation of PI(4,5)P 2 -enriched endosomal structures. Both approaches severely reduced virus production. Upon 5-phosphatase IV overexpression, Gag was no longer localized on the plasma membrane but instead was retargeted to late endosomes. Strikingly, in cells expressing Arf6/Q67L, Gag was redirected to the PI(4,5)P 2 -enriched vesicles and HIV-1 virions budded into these vesicles. These results demonstrate that PI(4,5)P 2 plays a key role in Gag targeting to the plasma membrane and thus serves as a cellular determinant of HIV-1 particle production.

1 July 2011 in Journal of Molecular Biology
Verified
Journal Article
Closed access
MCMary Ann Checkley
Mary Ann Checkley
BLBenjamin G. Luttge
Benjamin G. Luttge
Eric O. FreedEric O. Freed
Eric O. Freed

15 May 2002 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
Eric O. FreedEric O. Freed
Eric O. Freed